Group 1 - After the transaction, Yuandong Bio will indirectly hold a 30.6818% stake in Shanghai Chaoyang, making it a significant influence on the company [1] - The transaction is classified as a related party transaction due to the familial connections between the stakeholders involved [1] - Shanghai Chaoyang focuses on innovative drug development in oncology and autoimmune diseases, utilizing advanced technologies such as protein homeostasis and computer-aided drug design [1][2] Group 2 - Shanghai Chaoyang has a pipeline that includes projects HP001 and HP002, as well as candidates CY-002 and CY-007, and is developing a DAC platform for targeted therapies [2] - The R&D team is led by Dr. Zhao Liwen, who has extensive experience in drug development and has successfully brought multiple drugs into clinical trials [2] - Yuandong Bio views the acquisition of Shanghai Chaoyang's stake as a strategic move to accelerate its innovation transformation [3][4]